Wassil Jim

COO Wassil Jim sold 8,000 shares at blended $73.27, stock down 38.9% from 52-week high; company unprofitable with -$103.1M net income.

Wassil Jim, Chief Operating Officer of Vaxcyte, Inc., executed two separate sales on 2025-03-03 totaling 8,000 shares for $586,165.12 at prices of $73.07 and $73.84, reducing his holdings by 5.0% to 151,916 shares. The transaction occurs as the stock trades 38.9% below its 52-week high of $117.93, with a sharp 18.4% decline over the prior 30 days and 20.2% decline over 90 days. The company is fundamentally challenged: it reported a net loss of $103,124,000 for its most recent full fiscal year, indicating ongoing operational headwinds. His cross-ticker track record shows a 100% well-timed rate on prior sells, though his same-ticker history at PCVX remains incomplete due to recent February and January trades with outcomes still pending measurement. The confluence of significant stock weakness, unprofitable operations, and substantial share reduction by a senior executive deserves investor attention.

COO Wassil Jim sold 8,000 shares of PCVX for $689.8K on 2025-02-03; post-transaction holds 205.7K shares

Wassil Jim, the Chief Operating Officer, executed three separate sales totaling 8,000 shares for $689,790.43 at an average price of $86.22 on 2025-02-03. This represents a -3.7% reduction in his holdings, leaving him with 205,695 shares. The timing of this sale is notable: the stock is currently -26.6% from its 52-week high of $117.93, suggesting the executive sold near elevated valuations despite the company's unprofitable state (net income of $-103.1M). His cross-ticker track record shows 20 prior sells with a 100.00% well-timed rate at the 90-day mark, though his same-ticker history at PCVX reveals mixed recent performance with his prior five sales at this ticker showing 0 of 0 well-timed outcomes measurable at 90 days. The magnitude and execution across three tranches suggests a deliberate approach, warranting observation of whether this signals executive positioning in a currently loss-making operation.

COO Wassil Jim sold 8,000 shares across 3 transactions for $669,266.90 at $83.66 blended average on 2025-01-02.

Wassil Jim, the Chief Operating Officer of Vaxcyte, Inc., executed three separate sales totaling 8,000 shares (8.0K shares) for $669,266.90, reducing his holdings by 3.7% to 205,695 shares (205.7K shares). The sales occurred at prices ranging from $82.88 to $84.43, near the current price of $84.86, yet the stock has declined 8.8% over the prior 30 days and 23.8% over 90 days. Notably, across his prior five trades at PCVX, all five were sells executed in November and December 2024, each followed by declines ranging from 11.1% to 13.4% over the 30-day period, suggesting a consistent pattern of selling into downward price movement rather than ahead of broader deterioration. The company remains unprofitable with net income of $-103,124,000.00 over its most recent full fiscal year, providing fundamental context to sustained insider sales activity.

Wassil Jim (COO) sells 8,000 shares for $739,884.53 at blended avg $92.49 amid stock down -23.4% from 52-week high.

Wassil Jim, Chief Operating Officer of Vaxcyte, executed 3 separate sales totaling 8,000 shares for $739,884.53 on 2024-12-02, reducing his holdings from 213.7K to 205.7K shares (-3.7%). The sales occurred at prices ranging from $92.07 to $94.06 per share, while the stock currently trades at $90.37—below all transaction prices and down -23.4% from its 52-week high of $117.93. The company reported a net loss of $-103.1M in its most recent full fiscal year. Jim's prior PCVX sales (5 trades over the past two months in October and November) showed consistent post-sale declines of -7.0% to -13.4% over 30-day periods, suggesting his recent sales have coincided with sustained downward pressure. No measurable 90-day outcomes are yet available on those prior trades to assess longer-term timing accuracy at this ticker.

PCVX COO Wassil Jim sold 8,000 shares for $854.4K across 4 transactions on 2024-11-01 at blended average $106.80.

Wassil Jim, Chief Operating Officer of Vaxcyte, Inc., executed 4 separate sales totaling 8,000 shares for $854,422.61 on 2024-11-01, reducing his holdings from 213.7K to 205.7K shares (-3.7%). The sales occurred as the stock trades at $106.49, approximately 9.7% below its 52-week high of $117.93. His prior trade activity at PCVX shows 5 recent sales spanning September and October 2024, with 30-day returns ranging from -7.5% to +2.5%, while the underlying company remains unprofitable with net income of $-128.7M. The recent price action—30-day decline of 4.3% offset partially by a 90-day gain of 44.0%—contextualizes this as a sale occurring after substantial near-term gains but within a declining momentum window.

COO Wassil Jim sold 8,000 shares at $113.42–$114.95 (blended avg $114.24) on 2024-10-01 for $913,917.45 total.

Wassil Jim, Chief Operating Officer of Vaxcyte Inc., executed 3 separate sales totaling 8,000 shares for $913,917.45 across a narrow price band on 2024-10-01, reducing his holdings from 208,646 to 200,646 shares (a -3.8% net reduction). The sales occurred at an average price of $114.24, which is 2.9% above the current price of $111.08 and near the 52-week high of $117.12. Notably, the company posted a net loss of $-128,703,000.00 and remains unprofitable, yet the stock is up 42.8% over the past 90 days. His prior sales at this ticker show mixed timing: recent September 2024 sales posted 30-day returns of -0.7% and -1.6%, while the 0 of 0 measurable 90-day outcomes from prior sales at PCVX provide no statistical basis for evaluating timing skill at this specific ticker.

COO Wassil Jim sells 10,000 shares at $115.96 blended average for $1.2M just days before 52-week high.

Wassil Jim, Chief Operating Officer of Vaxcyte, executed 3 separate sales totaling 10,000 shares for $1,159,634.91 on 2024-09-16, reducing his holdings from 210.6K to 200.6K shares. The sales occurred at prices ($115.06, $116.14, $116.96) remarkably close to the stock's current 52-week high of $116.75, with the transaction-blended average of $115.96 tracking just -0.2% from the peak. Notably, Jim had sold 5 times at PCVX already within the preceding 13 days (2024-09-03), suggesting consistent liquidation through a recent strong rally. The company is unprofitable with net income of $-128,703,000.00 over its most recent fiscal year, and the 30-day and 90-day price appreciation of +47.5% and +60.2% respectively highlight the sharp run-up into which these sales were timed.

PCVX COO Wassil Jim sold 10,000 shares for $1.1M (blended avg $111.93) on 2024-09-03; retains 202.0K shares.

Wassil Jim, COO of Vaxcyte, executed 9 separate sales totaling 10,000 shares for $1,119,251.69 on 2024-09-03 at prices ranging from $108.01 to $117.02, representing a 4.7% reduction in his holdings to 202.0K shares. The sales occurred during a strong near-term price environment: PCVX trades at its 52-week high of $112.10 and has gained 51.6% over 30 days and 58.0% over 90 days. However, this positive momentum contrasts sharply with the company's financial condition: Vaxcyte posted a net loss of $128,703,000 over its most recent full fiscal year and remains unprofitable. The combination of substantial insider liquidation at elevated valuations alongside significant ongoing losses warrants scrutiny of the company's burn rate and path to profitability.